Kaye Scholer Advises Novartis on R&D Agreement with University of Pennsylvania to Study T-Cell Technology To Treat Cancer

August 6, 2012

Kaye Scholer is advising long-time client Novartis on its agreement for an exclusive global collaboration with University of Pennsylvania (Penn) to research, develop and commercialize targeted chimeric antigen receptor (CAR) immunotherapies for the treatment of cancers. In addition, the parties will jointly establish a new research and development facility on the Penn campus, called the Center for Advanced Cellular Therapies (CACT). Under the terms of the agreement, Penn grants Novartis an exclusive worldwide license to CARs developed through the collaboration for all indications. In addition Novartis will provide an up-front payment, research funding, funding for the establishment of the CACT and milestone payments for the achievement of certain clinical, regulatory and commercial milestones and royalty payments.

Led by Kaye Scholer Partner Adam Golden, Co-Chair of the firm’s Corporate Department, the other lawyers advising Novartis include IP Partner David Barr, Corporate Partner Andres Liivak, and Associates Holly Holloway and Viktoriya Karshenboyem, all out of the firm’s New York office.

Email Disclaimer